Abstract:
An erythorpoietin composition is provided to maintain erythoropoietin stable, increase safety of the erythoropoietin and prevent the erythoropoietin from being absorbed into the container wall surface by comprising the erythoropoietin, Tween 20, propylene glcyol and mannitol. An erythorpoietin composition with storage stability comprises 100-100,000 IU of erythorpoietin, 0.0002-0.5% of Tween 20, 0.005-0.3% of propylene glycol, and 0.01-3% of mannitol.
Abstract:
The present invention provides a composition comprising at least two binding molecules capable of neutralizing an influenza A virus, and each binding molecule is coupled to an epitope in a stem region of hemmaglutinin (HA) protein of the influenza A virus. The composition comprises: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; and ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition in the present invention effectively neutralizes both multi-influenza subtypes of phylogenetic groups 1 and 2 and can even be used with a chemical compound. Therefore, the composition is very useful for the prevention and treatment of diseases caused by an influenza virus.
Abstract:
The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method for manufacturing the same, and an anticancer drug composition comprising the same as an active ingredient. The dolastatin-10 derivative of the present invention is a novel synthetic compound which can be used for treating a tumor, slowing growth of tumors, and preventing an increase in number of tumors. For example, the dolastatin-10 derivative is effective to inhibit or prevent the growth of tumor in permalignant and malignant cells.
Abstract:
An expression vector for animal cell is provided to increase expression efficiency of a foreign gene in an animal cell by introducing at least one copy of MAR(matrix attachment region) DNA sequences to the 3' terminal of a gene transcription termination region. An expression vector for animal cell comprises a operatively linked promoter, a polynucleotide encoding a cloning site or a foreign product, and a transcription termination region of which 3' terminal comprises at least two copy of human beta-globin gene MAR DNA sequences in which the MAR sequences are adjacent together or separated by a coding or non-coding sequence. The polynucleotide is LacZ(beta-galactosidase polypeptide), immunoglobulin, GCSF(granulocyte colony stimulating factor) or EPO(erythropoietin) and the animal cell is CHO(Chinese hamster ovary), BHK(baby hamster kidney), NSO(non-secreting mouse myeloma) or human cell.
Abstract:
본발명은인플루엔자 A 바이러스의헤마글루티닌(HA) 단백질의줄기영역(stem region) 내에피토프에결합하는 2 이상의인플루엔자 A 바이러스중화결합분자를포함하는조성물로서, i) H1, H2, H5 및 H9으로구성된군으로부터선택되는하나이상의인플루엔자 A 바이러스서브타입을중화시킬수 있는제 1 결합분자; 및 ii) H1, H3, H5, H7 및 H9으로구성된군으로부터선택되는하나이상의인플루엔자 A 바이러스서브타입을중화시킬수 있는제 2 결합분자를포함하는조성물을제공한다. 본발명의혼합조성물은계통발생그룹 1 및 2의다중인플루엔자서브타입둘 다를효과적으로중화시키며, 화학적화합물과도병용하여사용할수 있으므로, 인플루엔자바이러스로인한질환의예방및 치료에매우유용하다.
Abstract:
본발명은인플루엔자 A 바이러스의헤마글루티닌(HA) 단백질의줄기영역(stem region) 내에피토프에결합하는 2 이상의인플루엔자 A 바이러스중화결합분자를포함하는조성물로서, i) H1, H2, H5 및 H9으로구성된군으로부터선택되는하나이상의인플루엔자 A 바이러스서브타입을중화시킬수 있는제 1 결합분자; 및 ii) H1, H3, H5, H7 및 H9으로구성된군으로부터선택되는하나이상의인플루엔자 A 바이러스서브타입을중화시킬수 있는제 2 결합분자를포함하는조성물을제공한다. 본발명의혼합조성물은계통발생그룹 1 및 2의다중인플루엔자서브타입둘 다를효과적으로중화시키며, 화학적화합물과도병용하여사용할수 있으므로, 인플루엔자바이러스로인한질환의예방및 치료에매우유용하다.